Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

111.79
+1.281.16%
Pre-market: 111.790.00000.00%08:19 EDT
Volume:1.02M
Turnover:114.90M
Market Cap:9.30B
PE:-34.80
High:115.69
Open:110.74
Low:108.03
Close:110.51
52wk High:130.05
52wk Low:54.09
Shares:83.15M
Float Shares:66.33M
Volume Ratio:1.39
T/O Rate:1.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.16
PE(LYR):-30.30

Loading ...

Kymera Therapeutics (KYMR) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Aug 13

Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR)

TIPRANKS
·
Aug 11

Immunic Appoints Elena Ridloff to Board of Directors

Reuters
·
Aug 11

Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says

MT Newswires Live
·
Aug 11

Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook

Reuters
·
Aug 07

Analyst Reiterates Buy on Kymera, Citing Favorable BROADEN2 Design and Compelling KT-621 Risk-Reward in Atopic Dermatitis

TIPRANKS
·
Aug 06

Kymera Therapeutics, Inc. : Citigroup Raises Target Price to $135 from $120

THOMSON REUTERS
·
Aug 06

Kymera Therapeutics price target raised to $139 from $133 at Barclays

TIPRANKS
·
Aug 06

Tenaya Therapeutics Q2 Net Loss Widens on Impairment Charge

Reuters
·
Aug 06

Vir Biotechnology Q2 Revenue Up, Beats Estimates on Astellas Payment

Reuters
·
Aug 06

Biopharma Firm Xencor's Q2 Revenue Beats on Royalty Revenue, Milestone Payments

Reuters
·
Aug 06

Editas Medicine Q2 Net Loss Narrows and Beats Estimates

Reuters
·
Aug 06

Kymera Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Kymera Therapeutics Posts Corporate Deck Outlining Push to Develop Oral Targeted Protein Degraders for Immunology

Reuters
·
Aug 05

Kymera Q2 2026 Earnings: Milestone Revenue Narrows Net Loss

TradingKey
·
Aug 05

Kymera Therapeutics Q2 Collaboration Revenue More than Doubles, Beats Estimates

Reuters
·
Aug 05

Earnings Flash (KYMR) Kymera Therapeutics Posts Q2 Loss $0.62 a Share, vs. FactSet Est of $0.71 Loss

MT Newswires Live
·
Aug 05

Kymera Therapeutics Q2 EPS $(0.62) Beats $(0.72) Estimate, Sales $65.000M Beat $31.165M Estimate

Benzinga Earnings
·
Aug 05

Kymera Therapeutics Q2 EPS USD -0.62

THOMSON REUTERS
·
Aug 05

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

THOMSON REUTERS
·
Aug 05